The survival, function, and hemolysis of human RBCs stored at 4°C in additive solution (AS‐1, AS‐3, or AS‐5) for 42 days and then biochemically modified, frozen, thawed, washed, and stored at 4°C in sodium chloride and glucose solution for 24 hours

Valeri, C. R.; Pivacek, Linda E.; Cassidy, George P.; Ragno, Gina

doi:10.1046/j.1537-2995.2000.40111341.x

Cited by 32 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study with 120 test and 60 control units, the system ameliorates many of the recognized cellular and metabolic features associated with the RBC storage lesion. RBCs stored in AS‐7 for 42 days had higher 24‐hour in vivo recovery than historic controls stored in the current US‐licensed RBC ASs . Furthermore, longer storage of RBCs for up to 56 days in AS‐7 maintains 24‐hour recoveries over the minimal requirements of the US FDA.…”

Section: Discussionmentioning

confidence: 92%

Additive solution‐7 reduces the red blood cell cold storage lesion

et al. 2014

View full text Add to dashboard Cite

BACKGROUND: Transfusion of long-stored red blood cells (RBCs) is associated with decreased in vivo RBC recovery, delivery of RBC breakdown products, and increased morbidity and mortality. Reducing the burden of this RBC "storage lesion" is a major challenge in transfusion medicine. Additive solution-7 (AS-7) is a new RBC storage solution designed to improve RBC metabolism by providing phosphate and increasing buff-ering capacity. STUDY DESIGN AND METHODS: Storage quality in AS-7 was measured in a prospective, randomized, three-center trial using units of whole blood from healthy human subjects whose RBCs were stored for up to 56 days in AS-7 (n = 120) or for 42 days in the control solution AS-1 (n = 60). RESULTS: Hemolysis and shedding of protein-containing microvesicles were significantly reduced in RBCs stored in AS-7 for 42 and 56 days compared with RBCs stored in AS-1. Autologous in vivo recoveries of RBCs stored in AS-7 was 88 ± 5% at 42 days (n = 27) and 82 ± 3% at 56 days (n = 27), exceeding recoveries of RBCs stored in currently used solutions. CONCLUSION: Increasing the phosphate, pH range, and buffer capacity of a RBC storage system allowed RBCs to be stored better and longer than currently approved storage systems. AS-7 ameliorates the long-term storage lesion resulting in significantly increased viability in vitro and in vivo. R ed blood cells (RBCs) are the most commonly transfused blood products. 1 However, the occurrence of antigenic blood groups on RBCs means that large numbers of RBC units are required in the inventories of regional blood systems and hospitals to assure that needed types are readily available. 2,3 RBCs for transfusion are prepared either from whole blood collected into CPD or CP2D or from apheresis collection into CP2D or ACD-A. After being processed into components, additional nutrients are provided to the RBCs for long-term storage in the form of an additive solution (AS). 4 RBCs for transfusion may also be leukoreduced before storage. These ASs were developed to provide volume for the dilution of metabolic waste; nutrients, especially adenine; and membrane protectant sugars. The current AS allow RBCs to be stored for up to 42 days with a mean in vivo recovery at the end of storage of 82 ± 7% From the (n = 641), 12% of samples showing less than 75% recovery, and hemolysis of 0.4% (n = 14,087) or 0.5% (n = 344, unpublished). 6 These performance characteristics suggest that ASs are effective and safe, and three ASs are licensed and in use in the United States, AS-1, AS-3, and AS-5, which perform equivalently. 7-9 Additional ASs have been approved for use in other countries including SAG-M, MAP, and PAGGSM for storage for 35 to 42 days. 10-12 The use of 42-day AS-stored RBC products has allowed the development of highly efficient national blood programs with approximately 95% of donated RBCs finding a recipient in Western countries. Recent studies have raised concerns about the safety of stored RBCs associated with the development of a clinically relevant RBC storage lesion, whic...

show abstract

Section: Discussionmentioning

confidence: 92%

Additive solution‐7 reduces the red blood cell cold storage lesion

et al. 2014

View full text Add to dashboard Cite

show abstract

“…ATP levels were statistically lower in treated RBCs than in controls, although the clinical significance of this decrease is not apparent. Studies are planned to evaluate the ability of PEN110‐treated RBCs to reverse this reduced ATP level following metabolic stimulation with pyruvate, inosine, phosphate, and adenine 16 . Intracellular potassium levels in treated units were equivalent to controls, suggesting that the permeability of the membrane to cations is not adversely affected by PEN110.…”

Section: Discussionmentioning

confidence: 99%

Process for the preparation of pathogen‐inactivated RBC concentrates by using PEN110 chemistry: preclinical studies

et al. 2002

Self Cite

View full text Add to dashboard Cite

show abstract

“…RBCs stored in AS-1, AS-3, or AS-5 at 4°C for 42 days can be biochemically modified with pyruvate, inosine, phosphate, and adenine (rejuvenation). The rejuvenated RBC can also be cryopreserved with acceptable Freeze-Thaw-Wash (FTW) in vitro with acceptable in vivo RBC recovery [11].…”

Section: Nbrl Methodsmentioning

confidence: 99%

Frozen Red Blood Cells in Transfusion

Chaudhari

2009

Medical Journal Armed Forces India

View full text Add to dashboard Cite

The survival, function, and hemolysis of human RBCs stored at 4°C in additive solution (AS‐1, AS‐3, or AS‐5) for 42 days and then biochemically modified, frozen, thawed, washed, and stored at 4°C in sodium chloride and glucose solution for 24 hours

Cited by 32 publications

References 15 publications

Additive solution‐7 reduces the red blood cell cold storage lesion

Additive solution‐7 reduces the red blood cell cold storage lesion

Process for the preparation of pathogen‐inactivated RBC concentrates by using PEN110 chemistry: preclinical studies

Frozen Red Blood Cells in Transfusion

Contact Info

Product

Resources

About